Daraxonrasib pancreatic cancer pill shows promise in trial

Daraxonrasib pancreatic cancer pill shows promise in trial

Newsora24 staff
3 minRead
0Views
0Reading now

Experts are describing a daily pill called daraxonrasib as the biggest breakthrough in pancreatic cancer treatment for decades. In early medical trials, the drug, given with chemotherapy, appeared to shrink tumours and possibly eliminate them in some patients with one of the deadliest and hardest-to-treat cancers.

According to the trial results, the cancer became undetectable on scans in one in 12 patients who received daraxonrasib alongside chemotherapy. Tumours stopped growing in almost all of the 61 participants, who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

How the early trial results were reported

Cancer Research UK called the findings “the biggest leap forward in decades” for people with pancreatic cancer. Its spokesperson, Dr Sam Godfrey, told the that the results were incredibly exciting. He said the drug had found a way of “drugging the undruggable”.

Dr Wungki Park, of Memorial Sloan Kettering Cancer Center in the United States, who is involved in the trial, said the results were extremely encouraging so far. He pointed to a higher share of tumour responses, deeper responses and a near doubling in the length of disease control, which he said may eventually lead to longer survival.

Daraxonrasib is a targeted inhibitor that has already been approved in the United States. It works by locking on to and shutting off RAS mutations, which are found in most pancreatic cancers and drive tumour growth. Dozens of other cancers, including lung and ovarian cancer, can carry similar mutations, so Dr Godfrey said he hoped the early success could be extended to other cancers.

Doctors warn that the benefits remain uncertain

Doctors stressed that it is unclear how long the drug might keep the disease under control, and that it should not be seen as a cure. The trial followed patients for about a year and a half on average, and some did not see their cancer return during that time.

Dr Godfrey said longer trials were vital. He cautioned that even when scans show no sign of cancer, patients do not necessarily know they are cancer-free until more time has passed. Prof Elena Garralda, chair of the European cancer conference where the work is being presented, said the combined treatment could potentially significantly improve overall survival, as well as the time before tumours grow again.

Chemotherapy alone can shrink tumours a little, but the cancer often grows back. Most patients with advanced disease survive months rather than years, which is why doctors hope the new approach could offer more time even if it cannot stop the cancer for good. Longer studies are needed to establish whether any of these cancers can go into remission, and for how long.

Pancreatic cancer’s toll and warning signs

Pancreatic cancer is notoriously hard to treat and has the lowest survival rate of all common cancers in the UK. It accounts for about 3% of all cancers in the United States and about 8% of cancer deaths there, killing around 53,000 people a year. In Britain, there are 11,500 diagnoses each year and around 10,200 deaths, according to Cancer Research UK.

The symptoms listed by health information include:

  • jaundice
  • itchy skin
  • darker urine and paler stools
  • unexplained weight loss
  • tiredness
  • high temperature

Leave an opinion

Your email address will not be published. Required fields are marked *

Story saved